Soapsoap personal page - To The Moon

Soapsoap

Soapsoap

No personal profile

24Follow

0Followers

0Topic

0Badge

2021-08-02

Hood

Ark Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple

2021-07-31

Nice

There are enough red flags that 'investors have to start considering de-risking,' warns star money manager

2021-07-20

Nice

Sorry, the original content has been removed

2021-07-18

Latest

Wall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World

2021-07-18

Okays

Sorry, the original content has been removed

2021-07-15

Please like

3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street

2021-07-15

Nice

3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3579087512345738","uuid":"3579087512345738","gmtCreate":1625221178081,"gmtModify":1626404751323,"name":"Soapsoap","pinyin":"soapsoap","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":24,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":805611283,"gmtCreate":1627875248142,"gmtModify":1703496991419,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Hood","listText":"Hood","text":"Hood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805611283","repostId":"1123481231","repostType":4,"repost":{"id":"1123481231","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627873809,"share":"https://ttm.financial/m/news/1123481231?lang=&edition=fundamental","pubTime":"2021-08-02 11:10","market":"us","language":"en","title":"Ark Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=1123481231","media":"Benzinga","summary":"Tesla Inc(NASDAQ:TSLA) bull Cathie Wood-led Ark Invest sold some of the shares in the electric vehic","content":"<p><b>Tesla Inc</b>(NASDAQ:TSLA) bull&nbsp;<b>Cathie Wood</b>-led Ark Invest sold some of the shares in the electric vehicle maker months after setting a steep price target on the stock as the investment management firm re-balances its portfolio.</p>\n<p>The popular investment firm sold 63,643 shares, estimated to be worth about $43.7 million, in the&nbsp;<b>Elon Musk</b>-led company on a day Wood said Tesla will follow&nbsp;<b>Apple Inc</b>(NASDAQ:AAPL) in capturing the lion's share of the sector's profits.</p>\n<p>Wood compared Tesla with Apple in an interview with RealVision and suggested a huge inefficiency in analyst research behind Tesla, as reported by&nbsp;Markets Insider.</p>\n<p>“We believe that the reason there's such a big inefficiency in Tesla's valuation is the short-term time horizon of analysts and the wrong analysts following it,” Woods said, as per the report.</p>\n<p>The popular investment firm, which counts Tesla as its biggest holding, had in March said the stock will hit&nbsp;$3,000 at the end of 2025.</p>\n<p>The New York-based investment firm had on Monday deployed the&nbsp;<b>Ark Innovation ETF</b>(NYSE:ARKK) to sell the shares in Tesla and also holds the stock via two other traded funds, namely, the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(NYSE:ARKW).</p>\n<p>Ark Invest last sold shares in Tesla in April when shares of the company were trading around&nbsp;$719 a piece.</p>\n<p>All three Ark ETFs count Tesla among their largest positions and together held 4.9 million shares, worth $3.34 billion, ahead of Friday’s trades.</p>\n<p>The popular investment firm also scooped over 1.85 million shares, estimated to be worth about $65.2 million, in&nbsp;<b>Robinhood Markets Inc</b>(NASDAQ:HOOD) as the shares of the company staged a recovery and closed higher just a day after a dismal debut.</p>\n<p>Robinhood shares closed&nbsp;0.95% higher at $35.15 on Friday, a day after losing over 8% on its trading debut.</p>\n<p>Ark deployed ARKK, ARKW and the&nbsp;<b>Ark Fintech Innovation ETF</b>(NYSE:ARKF) to buy the shares in Robinhood and the three ETFs held 4.6 million shares, worth $160.5 million, in Robinhood Markets.</p>\n<p>Some of the other key Ark Invest buys on Friday included&nbsp;<b>Pinterest Inc</b>(NYSE:PINS), and&nbsp;<b>UiPath Inc</b>(NYSE:PATH), and sells included&nbsp;<b>Pinduoduo Inc</b>(NASDAQ:PDD).</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ark Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArk Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-02 11:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tesla Inc</b>(NASDAQ:TSLA) bull&nbsp;<b>Cathie Wood</b>-led Ark Invest sold some of the shares in the electric vehicle maker months after setting a steep price target on the stock as the investment management firm re-balances its portfolio.</p>\n<p>The popular investment firm sold 63,643 shares, estimated to be worth about $43.7 million, in the&nbsp;<b>Elon Musk</b>-led company on a day Wood said Tesla will follow&nbsp;<b>Apple Inc</b>(NASDAQ:AAPL) in capturing the lion's share of the sector's profits.</p>\n<p>Wood compared Tesla with Apple in an interview with RealVision and suggested a huge inefficiency in analyst research behind Tesla, as reported by&nbsp;Markets Insider.</p>\n<p>“We believe that the reason there's such a big inefficiency in Tesla's valuation is the short-term time horizon of analysts and the wrong analysts following it,” Woods said, as per the report.</p>\n<p>The popular investment firm, which counts Tesla as its biggest holding, had in March said the stock will hit&nbsp;$3,000 at the end of 2025.</p>\n<p>The New York-based investment firm had on Monday deployed the&nbsp;<b>Ark Innovation ETF</b>(NYSE:ARKK) to sell the shares in Tesla and also holds the stock via two other traded funds, namely, the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(NYSE:ARKW).</p>\n<p>Ark Invest last sold shares in Tesla in April when shares of the company were trading around&nbsp;$719 a piece.</p>\n<p>All three Ark ETFs count Tesla among their largest positions and together held 4.9 million shares, worth $3.34 billion, ahead of Friday’s trades.</p>\n<p>The popular investment firm also scooped over 1.85 million shares, estimated to be worth about $65.2 million, in&nbsp;<b>Robinhood Markets Inc</b>(NASDAQ:HOOD) as the shares of the company staged a recovery and closed higher just a day after a dismal debut.</p>\n<p>Robinhood shares closed&nbsp;0.95% higher at $35.15 on Friday, a day after losing over 8% on its trading debut.</p>\n<p>Ark deployed ARKK, ARKW and the&nbsp;<b>Ark Fintech Innovation ETF</b>(NYSE:ARKF) to buy the shares in Robinhood and the three ETFs held 4.6 million shares, worth $160.5 million, in Robinhood Markets.</p>\n<p>Some of the other key Ark Invest buys on Friday included&nbsp;<b>Pinterest Inc</b>(NYSE:PINS), and&nbsp;<b>UiPath Inc</b>(NYSE:PATH), and sells included&nbsp;<b>Pinduoduo Inc</b>(NASDAQ:PDD).</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","ARKQ":"ARK Autonomous Technology & Robotics ETF","ARKW":"ARK Next Generation Internation ETF","ARKF":"ARK Fintech Innovation ETF","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123481231","content_text":"Tesla Inc(NASDAQ:TSLA) bull Cathie Wood-led Ark Invest sold some of the shares in the electric vehicle maker months after setting a steep price target on the stock as the investment management firm re-balances its portfolio.\nThe popular investment firm sold 63,643 shares, estimated to be worth about $43.7 million, in the Elon Musk-led company on a day Wood said Tesla will follow Apple Inc(NASDAQ:AAPL) in capturing the lion's share of the sector's profits.\nWood compared Tesla with Apple in an interview with RealVision and suggested a huge inefficiency in analyst research behind Tesla, as reported by Markets Insider.\n“We believe that the reason there's such a big inefficiency in Tesla's valuation is the short-term time horizon of analysts and the wrong analysts following it,” Woods said, as per the report.\nThe popular investment firm, which counts Tesla as its biggest holding, had in March said the stock will hit $3,000 at the end of 2025.\nThe New York-based investment firm had on Monday deployed the Ark Innovation ETF(NYSE:ARKK) to sell the shares in Tesla and also holds the stock via two other traded funds, namely, the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(NYSE:ARKW).\nArk Invest last sold shares in Tesla in April when shares of the company were trading around $719 a piece.\nAll three Ark ETFs count Tesla among their largest positions and together held 4.9 million shares, worth $3.34 billion, ahead of Friday’s trades.\nThe popular investment firm also scooped over 1.85 million shares, estimated to be worth about $65.2 million, in Robinhood Markets Inc(NASDAQ:HOOD) as the shares of the company staged a recovery and closed higher just a day after a dismal debut.\nRobinhood shares closed 0.95% higher at $35.15 on Friday, a day after losing over 8% on its trading debut.\nArk deployed ARKK, ARKW and the Ark Fintech Innovation ETF(NYSE:ARKF) to buy the shares in Robinhood and the three ETFs held 4.6 million shares, worth $160.5 million, in Robinhood Markets.\nSome of the other key Ark Invest buys on Friday included Pinterest Inc(NYSE:PINS), and UiPath Inc(NYSE:PATH), and sells included Pinduoduo Inc(NASDAQ:PDD).","news_type":1},"isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802932017,"gmtCreate":1627704992339,"gmtModify":1703495024494,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/802932017","repostId":"2155015426","repostType":4,"repost":{"id":"2155015426","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627701540,"share":"https://ttm.financial/m/news/2155015426?lang=&edition=fundamental","pubTime":"2021-07-31 11:19","market":"us","language":"en","title":"There are enough red flags that 'investors have to start considering de-risking,' warns star money manager","url":"https://stock-news.laohu8.com/highlight/detail?id=2155015426","media":"Dow Jones","summary":"Guggenheim's Minerd warns that the stock market could see a severe correction.\n\nInvestors may be ign","content":"<blockquote>\n Guggenheim's Minerd warns that the stock market could see a severe correction.\n</blockquote>\n<p>Investors may be ignoring mounting evidence that the delta variant of COVID-19 could be more troublesome than it is currently being given credit for by financial markets.</p>\n<p>That's the current stance of Scott Minerd, CIO of Guggenheim Investments, on the state of the U.S. stock market as COVID cases rise in some American states, fueled by the highly transmissible delta variant of coronavirus.</p>\n<p>In a research blog published on Friday , Minerd warns that the variant may be as contagious as chickenpox and other infectious diseases, according to recent research, and could cause a fresh run of disruptions to businesses, stymying the rebound from the global epidemic.</p>\n<p>On Tuesday, the CDC revived its recommendation that Americans wear masks indoors in public places, even if they have been vaccinated, in regions where COVID cases are rising. Public-health officials have said that COVID's delta variant is present in the nose and mouth at levels of more than 1,000 times the original virus.</p>\n<p>So even though vaccinated people are protected from its symptoms, they can still spread the delta variant, whose contagiousness is greater than the common cold, and on a par with the most-transmissible illnesses like chickenpox, epidemiologists have said.</p>\n<p>Minerd, though acknowledging that he isn't a medical expert in a CNBC interview, said that he is worried that the recent spike might see U.S. cases surge within six to eight weeks to levels not seen since last December at around 200,000.</p>\n<p>He referred to the current surge in the pandemic as \"mind-numbing,\" in the interview with the business television network.</p>\n<p>\"The increase in the absolute number of cases on a weekly basis appears to be similar to what we witnessed last summer when COVID infections began to spike going into the autumn,\" the Guggenheim CIO wrote in his blog .</p>\n<p>He pointed to the \"R\" transmission rate of the delta variant. He notes that the transmission rate of the initial strain of the coronavirus back in early 2020 \"was somewhere between two and three, meaning that if someone were exposed to the virus, they would, on average, infect two to three more people.\"</p>\n<p>If the R rate of an infectious disease is less than 1, the disease will \"eventually peter out,\" but if it is greater than 1 it will spread, he noted.</p>\n<p>The R rate of the delta variant is around six, \"which is two to three times more transmissible than the initial COVID strain,\" Minerd wrote.</p>\n<p>Minerd speculated that the stock market could see a 10% or 20% correction, due to the economic slowdown resulting from a fresh delta-fueled rise in case counts.</p>\n<p>\"The potential resurgence of the pandemic is happening during a seasonally weak period for risk assets. This increases the probability of downside risk,\" he wrote.</p>\n<p>On Friday afternoon , the Dow Jones Industrial Average and S&amp;P 500 index were off less than 1% from their July 26 record highs, while the Nasdaq Composite Index was off a little over 1% from its record earlier this week.</p>\n<p>To be sure, a number of analysts view the market as richly valued and make the case that its current loftiness might merit a pullback, especially if American corporations have reached peak earnings and the economy has seen peak growth in the aftermath of the pandemic.</p>\n<p>Still, Minerd told the business network that a correction, although painful for investors, could present \"a great buying opportunity.\"</p>\n<p>Against his downside backdrop, Minerd also sees the possibility that the benchmark 10-year Treasury rate could fall from 1.23% to around 0.65%, which would bring the yields for the government debt, used to price everything from mortgages to car loans, to its lowest level since Octoberand September of 2020.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>There are enough red flags that 'investors have to start considering de-risking,' warns star money manager</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThere are enough red flags that 'investors have to start considering de-risking,' warns star money manager\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-31 11:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n Guggenheim's Minerd warns that the stock market could see a severe correction.\n</blockquote>\n<p>Investors may be ignoring mounting evidence that the delta variant of COVID-19 could be more troublesome than it is currently being given credit for by financial markets.</p>\n<p>That's the current stance of Scott Minerd, CIO of Guggenheim Investments, on the state of the U.S. stock market as COVID cases rise in some American states, fueled by the highly transmissible delta variant of coronavirus.</p>\n<p>In a research blog published on Friday , Minerd warns that the variant may be as contagious as chickenpox and other infectious diseases, according to recent research, and could cause a fresh run of disruptions to businesses, stymying the rebound from the global epidemic.</p>\n<p>On Tuesday, the CDC revived its recommendation that Americans wear masks indoors in public places, even if they have been vaccinated, in regions where COVID cases are rising. Public-health officials have said that COVID's delta variant is present in the nose and mouth at levels of more than 1,000 times the original virus.</p>\n<p>So even though vaccinated people are protected from its symptoms, they can still spread the delta variant, whose contagiousness is greater than the common cold, and on a par with the most-transmissible illnesses like chickenpox, epidemiologists have said.</p>\n<p>Minerd, though acknowledging that he isn't a medical expert in a CNBC interview, said that he is worried that the recent spike might see U.S. cases surge within six to eight weeks to levels not seen since last December at around 200,000.</p>\n<p>He referred to the current surge in the pandemic as \"mind-numbing,\" in the interview with the business television network.</p>\n<p>\"The increase in the absolute number of cases on a weekly basis appears to be similar to what we witnessed last summer when COVID infections began to spike going into the autumn,\" the Guggenheim CIO wrote in his blog .</p>\n<p>He pointed to the \"R\" transmission rate of the delta variant. He notes that the transmission rate of the initial strain of the coronavirus back in early 2020 \"was somewhere between two and three, meaning that if someone were exposed to the virus, they would, on average, infect two to three more people.\"</p>\n<p>If the R rate of an infectious disease is less than 1, the disease will \"eventually peter out,\" but if it is greater than 1 it will spread, he noted.</p>\n<p>The R rate of the delta variant is around six, \"which is two to three times more transmissible than the initial COVID strain,\" Minerd wrote.</p>\n<p>Minerd speculated that the stock market could see a 10% or 20% correction, due to the economic slowdown resulting from a fresh delta-fueled rise in case counts.</p>\n<p>\"The potential resurgence of the pandemic is happening during a seasonally weak period for risk assets. This increases the probability of downside risk,\" he wrote.</p>\n<p>On Friday afternoon , the Dow Jones Industrial Average and S&amp;P 500 index were off less than 1% from their July 26 record highs, while the Nasdaq Composite Index was off a little over 1% from its record earlier this week.</p>\n<p>To be sure, a number of analysts view the market as richly valued and make the case that its current loftiness might merit a pullback, especially if American corporations have reached peak earnings and the economy has seen peak growth in the aftermath of the pandemic.</p>\n<p>Still, Minerd told the business network that a correction, although painful for investors, could present \"a great buying opportunity.\"</p>\n<p>Against his downside backdrop, Minerd also sees the possibility that the benchmark 10-year Treasury rate could fall from 1.23% to around 0.65%, which would bring the yields for the government debt, used to price everything from mortgages to car loans, to its lowest level since Octoberand September of 2020.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155015426","content_text":"Guggenheim's Minerd warns that the stock market could see a severe correction.\n\nInvestors may be ignoring mounting evidence that the delta variant of COVID-19 could be more troublesome than it is currently being given credit for by financial markets.\nThat's the current stance of Scott Minerd, CIO of Guggenheim Investments, on the state of the U.S. stock market as COVID cases rise in some American states, fueled by the highly transmissible delta variant of coronavirus.\nIn a research blog published on Friday , Minerd warns that the variant may be as contagious as chickenpox and other infectious diseases, according to recent research, and could cause a fresh run of disruptions to businesses, stymying the rebound from the global epidemic.\nOn Tuesday, the CDC revived its recommendation that Americans wear masks indoors in public places, even if they have been vaccinated, in regions where COVID cases are rising. Public-health officials have said that COVID's delta variant is present in the nose and mouth at levels of more than 1,000 times the original virus.\nSo even though vaccinated people are protected from its symptoms, they can still spread the delta variant, whose contagiousness is greater than the common cold, and on a par with the most-transmissible illnesses like chickenpox, epidemiologists have said.\nMinerd, though acknowledging that he isn't a medical expert in a CNBC interview, said that he is worried that the recent spike might see U.S. cases surge within six to eight weeks to levels not seen since last December at around 200,000.\nHe referred to the current surge in the pandemic as \"mind-numbing,\" in the interview with the business television network.\n\"The increase in the absolute number of cases on a weekly basis appears to be similar to what we witnessed last summer when COVID infections began to spike going into the autumn,\" the Guggenheim CIO wrote in his blog .\nHe pointed to the \"R\" transmission rate of the delta variant. He notes that the transmission rate of the initial strain of the coronavirus back in early 2020 \"was somewhere between two and three, meaning that if someone were exposed to the virus, they would, on average, infect two to three more people.\"\nIf the R rate of an infectious disease is less than 1, the disease will \"eventually peter out,\" but if it is greater than 1 it will spread, he noted.\nThe R rate of the delta variant is around six, \"which is two to three times more transmissible than the initial COVID strain,\" Minerd wrote.\nMinerd speculated that the stock market could see a 10% or 20% correction, due to the economic slowdown resulting from a fresh delta-fueled rise in case counts.\n\"The potential resurgence of the pandemic is happening during a seasonally weak period for risk assets. This increases the probability of downside risk,\" he wrote.\nOn Friday afternoon , the Dow Jones Industrial Average and S&P 500 index were off less than 1% from their July 26 record highs, while the Nasdaq Composite Index was off a little over 1% from its record earlier this week.\nTo be sure, a number of analysts view the market as richly valued and make the case that its current loftiness might merit a pullback, especially if American corporations have reached peak earnings and the economy has seen peak growth in the aftermath of the pandemic.\nStill, Minerd told the business network that a correction, although painful for investors, could present \"a great buying opportunity.\"\nAgainst his downside backdrop, Minerd also sees the possibility that the benchmark 10-year Treasury rate could fall from 1.23% to around 0.65%, which would bring the yields for the government debt, used to price everything from mortgages to car loans, to its lowest level since Octoberand September of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178391104,"gmtCreate":1626787289908,"gmtModify":1703765151445,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178391104","repostId":"1105124055","repostType":4,"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173961398,"gmtCreate":1626601300814,"gmtModify":1703762232512,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173961398","repostId":"1139907709","repostType":4,"repost":{"id":"1139907709","kind":"news","pubTimestamp":1626568617,"share":"https://ttm.financial/m/news/1139907709?lang=&edition=fundamental","pubTime":"2021-07-18 08:36","market":"us","language":"en","title":"Wall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World","url":"https://stock-news.laohu8.com/highlight/detail?id=1139907709","media":"Benzinga","summary":"Does crime pay?\nIn August 1988, French authorities arrested an American expatriate named Thomas F. Q","content":"<p><i>Does crime pay?</i></p>\n<p>In August 1988, French authorities arrested an American expatriate named&nbsp;<b>Thomas F. Quinn</b>&nbsp;for orchestrating a global securities scheme that defrauded investors out of $500 million.</p>\n<p>As an unapologetic financial miscreant with a lifelong penchant for fraud, the French escapade represented something of a career peak for Quinn, whose flair of swindling took on an astonishing level of organizing that left no corner of the world untouched.</p>\n<p><b>Illusory Assets For Sale:</b>Thomas Francis Quinn was born in Brooklyn in 1932; his father drove a cement truck and his mother was a housewife who made extra money selling clothing and jewelry from the family’s garage.</p>\n<p>Quinn was an altar boy in his childhood and was the first member of his family to pursue higher education, graduating from St. John’s University Law School and passing the bar in 1962.</p>\n<p>Quinn opted to go into business for himself, starting a brokerage firm in New York called&nbsp;<b>Thomas, Williams &amp; Lee.</b>The main focus of this firm became the promotion of&nbsp;<b>Kent Industries,</b>a company that claimed to own Florida property valued at $2 million.</p>\n<p>There was a slight problem —&nbsp;Kent Industries didn’t own anything in the Sunshine State, and this inconvenient fact helped to introduce Quinn to the U.S. Securities and Exchange Commission (SEC).</p>\n<p>Long story short: Quinn received a lifetime banishment from the SEC in 1966 from doing business with brokers and dealers thanks to what the agency defined as his “flagrant fraudulent practices” related to the Kent Industries assets, which the regulator considered to be “almost completely illusory.”</p>\n<p>The U.S. Department of Justice (DOJ) was a bit slower in dealing with Quinn, but by 1970 he was sent to jail for six months and was later permanently disbarred from practicing law.</p>\n<p><b>A Job With The Mob:</b>Prior to losing his law license, Quinn gained a partnership in a New York-based securities law firm that set off several alarms among federal law enforcement agencies. Indeed, an FBI report from 1983 recalled this firm’s chief focus was being responsible for the “funds of hoodlum-controlled companies.”</p>\n<p>Quinn was on both the FBI’s and SEC’s respective radars in the early 1980s for his role with two companies,<b>Sundance Gold Mining</b>&nbsp;and&nbsp;<b>Aquarius Gold Exploration</b>, that claimed to have discovered gold in Suriname. The companies created a flurry of excitement among investors, but an investigation into their operations found a hitherto undeclared connection with the&nbsp;<b>Genovese crime family.</b></p>\n<p>The SEC filed a civil complaint against Quinn in 1983, charging him with fraudulently manipulating and promoting the companies’ stocks.</p>\n<p>Three years later, he reached a settlement with the regulator by agreeing to permanently stay away from anything related to securities.</p>\n<p>The FBI, despite finding Mafia fingerprints in Quinn’s business affairs, declined to press charges against him.</p>\n<p>Realizing that he wore out his welcome in his home country, Quinn and his common-law wife&nbsp;<b>Rochelle Rothfleisch</b>&nbsp;decided to relocate to France and to up his game to an unprecedented operation.</p>\n<p><b>Boiler Room Follies:</b>The circumstances and details of how Quinn built his swindling masterpiece are a bit fuzzy, but it is believed that the scheme was first hatched in 1984 and was coordinated out of his $6 million villa in the south of France.</p>\n<p>Quinn set up an archipelago of offices in several European countries and in Dubai, Jamaica and the tiny South Pacific island nation of Vanuatu, and he gave them phony names that sounded similar to respectable brokerages.</p>\n<p>Each office was staffed with salesmen who were tasked to sell stocks for 20 U.S. corporations to individual investors around the world. The stocks in question were mostly shell companies trading on the over-the-counter exchanges that Quinn picked up for pennies, but they were resold by Quinn’s salesmen at inflated amounts.</p>\n<p>The investors were culled from mailing lists sold by publishing companies and professional organizations, as well as from respondents to advertisements placed in newsletters focused on the over-the-counter markets.</p>\n<p>Quinn’s henchmen would telephone the investors —&nbsp;nearly all of whom were novices to investing —&nbsp;and do a high-pressure sales spiel that, more often than not, resulted in the separation of the gullible targets from their money.</p>\n<p>Quinn’s team aimed at European, Australian, Middle Eastern and Hong Kong neophyte investors. The only country off-limits from this scheme was the U.S. Quinn was already on the FBI’s radar and the last thing he wanted was to give them cause to pursue him anew.</p>\n<p><b>A Temporary Setback:</b>&nbsp;In 1988, Quinn’s arrest in France&nbsp;saw him charged with securities fraud, forgery of administrative documents and the possession of two fake Greek passports. His detention and the subsequent arrest of 20 of his salesmen created a fascinating dilemma for banking and law enforcement agencies in multiple countries.</p>\n<p>For starters, no one could easily figure out where the majority of Quinn’s $500 million in ill-gotten gains wound up.&nbsp;Transfers were traced through banks in Switzerland, Luxembourg and Gibraltar, as well as the beleaguered&nbsp;<b>Bank of Credit and Commerce International</b>&nbsp;in Tampa, Florida, which gained national attention as a favored depository for those involved in drug money laundering. But where the money eventually landed was anyone’s guess, and Quinn’s talent for adopting aliases to cover his business tracks confounded investigators.</p>\n<p>Also, it was unclear regarding how many people were swindled. A pair of class-action lawsuits brought out a total of 500 people trying to regain their money, but some observers of this case speculated the number could have been higher — some investors might have seen Quinn’s scam as a means of evading local taxes and foreign currency exchanges and would then have to answer to their authorities if this chicanery came to light.</p>\n<p>The SEC got into the picture because the stocks being sold in the scheme were all U.S. companies. The agency hosted a meeting in Washington D.C.&nbsp;with law enforcement officers and prosecutors from eight European countries and Australia, with the hopes of sorting out the mess. But since no Americans were defrauded in this elaborate charade, Quinn did not face criminal charges in his own country, although the SEC temporarily froze his U.S. assets.</p>\n<p>In France, Quinn was initially released after agreeing to reimburse his French victims but was arrested again when the Swiss government demanded his extradition.</p>\n<p>He came to trial in 1991 and was only sentenced to four years in prison,&nbsp;but his sentence was reduced to include time served and he was extradited to Switzerland.</p>\n<p>His Alpine detention was brief and by the mid-1990s he returned to the U.S. and rented a luxury home in Greenwich, Connecticut, a swanky suburb of New York City.</p>\n<p><b>An Eventual Stumble:</b>One of Quinn’s neighbors in Greenwich was<b>Martin Frankel,</b>a financier with his own addiction to swindling.</p>\n<p>In 1999, the Wall Street Journal used anonymous “people familiar with the matter” to claim Quinn assisted Frankel in his efforts to raise money for a controlled investment fund designed to buy insurance companies —&nbsp;but this turned out to be an embezzlement scam that resulted in Frankel fleeing the U.S. to Germany on a phony passport.</p>\n<p>Frankel was eventually extradited and spent nearly two decades in prison, but Quinn was never charged for being a partner in Frankel’s shenanigans.</p>\n<p>For most of the 1990s and the 2000s, Quinn kept a very low public profile, although law enforcement tracked his travels to such far-flung places as the Maldives and the United Arab Emirates.</p>\n<p>In 2004, he made a rare appearance at the Irish Derby as the co-owner of the winning thoroughbred Grey Swallow. Photographs of Quinn with the winning racehorse marked the only time that he was ever photographed in a public gathering. (Copyright restrictions prevent us from reprinting the photograph here, butthis linkon the RTE website shows Quinn, standing second from right, at the conclusion of the championship race.)</p>\n<p>In November 2009, Quinn’s luck finally ran out. On a trip back from Ireland to New York’s JFK International Airport, he was arrested for his role within a ring of embezzlers that sought to defraud a pair of British telecommunications companies out of more than $60 million. The scheme had the global hallmarks of Quinn’s earlier criminal triumph, with funds being disbursed to seven countries across four continents.</p>\n<p>Quinn was immediately jailed upon his arrest and was denied bail because it was feared he would attempt to flee the country. He eventually pleaded guilty to a single count of wire fraud and, despite exhortations to avoid prison due to health problems, he was sentenced in March 2013 to 84 months in prison. He was released in May 2016.</p>\n<p>What became of Quinn since his release is unknown. No obituary for him has been published, and he would be 89 years old if he is still alive.</p>\n<p>One information-tracking website listed him residing at a Brooklyn address, but the website also listed an accompanying telephone number that is not in service. Any readers who may have information on Quinn’s whereabouts should contact us and we will offer an update on his story.</p>\n<p>Quinn rarely spoke to anyone about his criminal activities.&nbsp;During an investigative session after his final arrest, he reportedly would only answer questions through a series of eyelid blinks. When a reporter sought to interview him in 1995, he demanded his privacy.</p>\n<p>\"Just forget me,\" Quinn said. \"I've got a lot of trouble and a lot of personal grief. I'm just trying to get on with my life. I'm not in the securities business and never will be again.\"</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/government/21/07/21990476/wall-street-crime-and-punishment-thomas-f-quinns-mad-mad-mad-mad-world><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Does crime pay?\nIn August 1988, French authorities arrested an American expatriate named Thomas F. Quinn for orchestrating a global securities scheme that defrauded investors out of $500 million.\nAs ...</p>\n\n<a href=\"https://www.benzinga.com/government/21/07/21990476/wall-street-crime-and-punishment-thomas-f-quinns-mad-mad-mad-mad-world\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/government/21/07/21990476/wall-street-crime-and-punishment-thomas-f-quinns-mad-mad-mad-mad-world","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139907709","content_text":"Does crime pay?\nIn August 1988, French authorities arrested an American expatriate named Thomas F. Quinn for orchestrating a global securities scheme that defrauded investors out of $500 million.\nAs an unapologetic financial miscreant with a lifelong penchant for fraud, the French escapade represented something of a career peak for Quinn, whose flair of swindling took on an astonishing level of organizing that left no corner of the world untouched.\nIllusory Assets For Sale:Thomas Francis Quinn was born in Brooklyn in 1932; his father drove a cement truck and his mother was a housewife who made extra money selling clothing and jewelry from the family’s garage.\nQuinn was an altar boy in his childhood and was the first member of his family to pursue higher education, graduating from St. John’s University Law School and passing the bar in 1962.\nQuinn opted to go into business for himself, starting a brokerage firm in New York called Thomas, Williams & Lee.The main focus of this firm became the promotion of Kent Industries,a company that claimed to own Florida property valued at $2 million.\nThere was a slight problem — Kent Industries didn’t own anything in the Sunshine State, and this inconvenient fact helped to introduce Quinn to the U.S. Securities and Exchange Commission (SEC).\nLong story short: Quinn received a lifetime banishment from the SEC in 1966 from doing business with brokers and dealers thanks to what the agency defined as his “flagrant fraudulent practices” related to the Kent Industries assets, which the regulator considered to be “almost completely illusory.”\nThe U.S. Department of Justice (DOJ) was a bit slower in dealing with Quinn, but by 1970 he was sent to jail for six months and was later permanently disbarred from practicing law.\nA Job With The Mob:Prior to losing his law license, Quinn gained a partnership in a New York-based securities law firm that set off several alarms among federal law enforcement agencies. Indeed, an FBI report from 1983 recalled this firm’s chief focus was being responsible for the “funds of hoodlum-controlled companies.”\nQuinn was on both the FBI’s and SEC’s respective radars in the early 1980s for his role with two companies,Sundance Gold Mining and Aquarius Gold Exploration, that claimed to have discovered gold in Suriname. The companies created a flurry of excitement among investors, but an investigation into their operations found a hitherto undeclared connection with the Genovese crime family.\nThe SEC filed a civil complaint against Quinn in 1983, charging him with fraudulently manipulating and promoting the companies’ stocks.\nThree years later, he reached a settlement with the regulator by agreeing to permanently stay away from anything related to securities.\nThe FBI, despite finding Mafia fingerprints in Quinn’s business affairs, declined to press charges against him.\nRealizing that he wore out his welcome in his home country, Quinn and his common-law wife Rochelle Rothfleisch decided to relocate to France and to up his game to an unprecedented operation.\nBoiler Room Follies:The circumstances and details of how Quinn built his swindling masterpiece are a bit fuzzy, but it is believed that the scheme was first hatched in 1984 and was coordinated out of his $6 million villa in the south of France.\nQuinn set up an archipelago of offices in several European countries and in Dubai, Jamaica and the tiny South Pacific island nation of Vanuatu, and he gave them phony names that sounded similar to respectable brokerages.\nEach office was staffed with salesmen who were tasked to sell stocks for 20 U.S. corporations to individual investors around the world. The stocks in question were mostly shell companies trading on the over-the-counter exchanges that Quinn picked up for pennies, but they were resold by Quinn’s salesmen at inflated amounts.\nThe investors were culled from mailing lists sold by publishing companies and professional organizations, as well as from respondents to advertisements placed in newsletters focused on the over-the-counter markets.\nQuinn’s henchmen would telephone the investors — nearly all of whom were novices to investing — and do a high-pressure sales spiel that, more often than not, resulted in the separation of the gullible targets from their money.\nQuinn’s team aimed at European, Australian, Middle Eastern and Hong Kong neophyte investors. The only country off-limits from this scheme was the U.S. Quinn was already on the FBI’s radar and the last thing he wanted was to give them cause to pursue him anew.\nA Temporary Setback: In 1988, Quinn’s arrest in France saw him charged with securities fraud, forgery of administrative documents and the possession of two fake Greek passports. His detention and the subsequent arrest of 20 of his salesmen created a fascinating dilemma for banking and law enforcement agencies in multiple countries.\nFor starters, no one could easily figure out where the majority of Quinn’s $500 million in ill-gotten gains wound up. Transfers were traced through banks in Switzerland, Luxembourg and Gibraltar, as well as the beleaguered Bank of Credit and Commerce International in Tampa, Florida, which gained national attention as a favored depository for those involved in drug money laundering. But where the money eventually landed was anyone’s guess, and Quinn’s talent for adopting aliases to cover his business tracks confounded investigators.\nAlso, it was unclear regarding how many people were swindled. A pair of class-action lawsuits brought out a total of 500 people trying to regain their money, but some observers of this case speculated the number could have been higher — some investors might have seen Quinn’s scam as a means of evading local taxes and foreign currency exchanges and would then have to answer to their authorities if this chicanery came to light.\nThe SEC got into the picture because the stocks being sold in the scheme were all U.S. companies. The agency hosted a meeting in Washington D.C. with law enforcement officers and prosecutors from eight European countries and Australia, with the hopes of sorting out the mess. But since no Americans were defrauded in this elaborate charade, Quinn did not face criminal charges in his own country, although the SEC temporarily froze his U.S. assets.\nIn France, Quinn was initially released after agreeing to reimburse his French victims but was arrested again when the Swiss government demanded his extradition.\nHe came to trial in 1991 and was only sentenced to four years in prison, but his sentence was reduced to include time served and he was extradited to Switzerland.\nHis Alpine detention was brief and by the mid-1990s he returned to the U.S. and rented a luxury home in Greenwich, Connecticut, a swanky suburb of New York City.\nAn Eventual Stumble:One of Quinn’s neighbors in Greenwich wasMartin Frankel,a financier with his own addiction to swindling.\nIn 1999, the Wall Street Journal used anonymous “people familiar with the matter” to claim Quinn assisted Frankel in his efforts to raise money for a controlled investment fund designed to buy insurance companies — but this turned out to be an embezzlement scam that resulted in Frankel fleeing the U.S. to Germany on a phony passport.\nFrankel was eventually extradited and spent nearly two decades in prison, but Quinn was never charged for being a partner in Frankel’s shenanigans.\nFor most of the 1990s and the 2000s, Quinn kept a very low public profile, although law enforcement tracked his travels to such far-flung places as the Maldives and the United Arab Emirates.\nIn 2004, he made a rare appearance at the Irish Derby as the co-owner of the winning thoroughbred Grey Swallow. Photographs of Quinn with the winning racehorse marked the only time that he was ever photographed in a public gathering. (Copyright restrictions prevent us from reprinting the photograph here, butthis linkon the RTE website shows Quinn, standing second from right, at the conclusion of the championship race.)\nIn November 2009, Quinn’s luck finally ran out. On a trip back from Ireland to New York’s JFK International Airport, he was arrested for his role within a ring of embezzlers that sought to defraud a pair of British telecommunications companies out of more than $60 million. The scheme had the global hallmarks of Quinn’s earlier criminal triumph, with funds being disbursed to seven countries across four continents.\nQuinn was immediately jailed upon his arrest and was denied bail because it was feared he would attempt to flee the country. He eventually pleaded guilty to a single count of wire fraud and, despite exhortations to avoid prison due to health problems, he was sentenced in March 2013 to 84 months in prison. He was released in May 2016.\nWhat became of Quinn since his release is unknown. No obituary for him has been published, and he would be 89 years old if he is still alive.\nOne information-tracking website listed him residing at a Brooklyn address, but the website also listed an accompanying telephone number that is not in service. Any readers who may have information on Quinn’s whereabouts should contact us and we will offer an update on his story.\nQuinn rarely spoke to anyone about his criminal activities. During an investigative session after his final arrest, he reportedly would only answer questions through a series of eyelid blinks. When a reporter sought to interview him in 1995, he demanded his privacy.\n\"Just forget me,\" Quinn said. \"I've got a lot of trouble and a lot of personal grief. I'm just trying to get on with my life. I'm not in the securities business and never will be again.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173963705,"gmtCreate":1626601261107,"gmtModify":1703762232029,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Okays","listText":"Okays","text":"Okays","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173963705","repostId":"1123523681","repostType":4,"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147641989,"gmtCreate":1626357526641,"gmtModify":1703758593400,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147641989","repostId":"2151526974","repostType":4,"repost":{"id":"2151526974","kind":"highlight","pubTimestamp":1626355620,"share":"https://ttm.financial/m/news/2151526974?lang=&edition=fundamental","pubTime":"2021-07-15 21:27","market":"us","language":"en","title":"3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2151526974","media":"Motley Fool","summary":"Analysts' high-water price targets imply some serious gains for these companies.","content":"<p>Despite the stock market hitting seemingly <a href=\"https://laohu8.com/S/AONE.U\">one</a> new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.</p>\n<p>But growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.</p>\n<h2>Vaxart: Implied upside of 158%</h2>\n<p>The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.</p>\n<p>For Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.</p>\n<p>But it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.</p>\n<p>Back on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.</p>\n<p>Though Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.</p>\n<h2>Columbia Care: Implied upside of 180%</h2>\n<p>Wall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is <b>Columbia Care</b> (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.</p>\n<p>Columbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.</p>\n<p>Although the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.</p>\n<p>Additionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.</p>\n<p>The last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.</p>\n<p>To be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 329%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.</p>\n<p>The bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.</p>\n<p>Inovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.</p>\n<p>On the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.</p>\n<p>What's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.</p>\n<p>In other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药","VXRT":"Vaxart, Inc"},"source_url":"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151526974","content_text":"Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.\nBut growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.\nVaxart: Implied upside of 158%\nThe first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.\nFor Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.\nBut it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.\nBack on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.\nThough Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.\nColumbia Care: Implied upside of 180%\nWall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is Columbia Care (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.\nColumbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.\nAlthough the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.\nAdditionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.\nThe last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.\nTo be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.\nInovio Pharmaceuticals: Implied upside of 329%\nBut the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.\nThe bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.\nInovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.\nOn the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.\nWhat's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.\nIn other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147629369,"gmtCreate":1626356701251,"gmtModify":1703758562623,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147629369","repostId":"2151526974","repostType":4,"repost":{"id":"2151526974","kind":"highlight","pubTimestamp":1626355620,"share":"https://ttm.financial/m/news/2151526974?lang=&edition=fundamental","pubTime":"2021-07-15 21:27","market":"us","language":"en","title":"3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2151526974","media":"Motley Fool","summary":"Analysts' high-water price targets imply some serious gains for these companies.","content":"<p>Despite the stock market hitting seemingly <a href=\"https://laohu8.com/S/AONE.U\">one</a> new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.</p>\n<p>But growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.</p>\n<h2>Vaxart: Implied upside of 158%</h2>\n<p>The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.</p>\n<p>For Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.</p>\n<p>But it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.</p>\n<p>Back on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.</p>\n<p>Though Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.</p>\n<h2>Columbia Care: Implied upside of 180%</h2>\n<p>Wall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is <b>Columbia Care</b> (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.</p>\n<p>Columbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.</p>\n<p>Although the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.</p>\n<p>Additionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.</p>\n<p>The last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.</p>\n<p>To be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 329%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.</p>\n<p>The bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.</p>\n<p>Inovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.</p>\n<p>On the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.</p>\n<p>What's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.</p>\n<p>In other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药","VXRT":"Vaxart, Inc"},"source_url":"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151526974","content_text":"Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.\nBut growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.\nVaxart: Implied upside of 158%\nThe first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.\nFor Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.\nBut it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.\nBack on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.\nThough Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.\nColumbia Care: Implied upside of 180%\nWall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is Columbia Care (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.\nColumbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.\nAlthough the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.\nAdditionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.\nThe last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.\nTo be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.\nInovio Pharmaceuticals: Implied upside of 329%\nBut the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.\nThe bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.\nInovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.\nOn the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.\nWhat's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.\nIn other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.","news_type":1},"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":802932017,"gmtCreate":1627704992339,"gmtModify":1703495024494,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/802932017","repostId":"2155015426","repostType":4,"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178391104,"gmtCreate":1626787289908,"gmtModify":1703765151445,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178391104","repostId":"1105124055","repostType":4,"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173963705,"gmtCreate":1626601261107,"gmtModify":1703762232029,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Okays","listText":"Okays","text":"Okays","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173963705","repostId":"1123523681","repostType":4,"repost":{"id":"1123523681","kind":"news","pubTimestamp":1626569903,"share":"https://ttm.financial/m/news/1123523681?lang=&edition=fundamental","pubTime":"2021-07-18 08:58","market":"us","language":"en","title":"The story behind the savvy ‘Mystery Broker’ and where he sees the market going now","url":"https://stock-news.laohu8.com/highlight/detail?id=1123523681","media":"CNBC","summary":"“So, there’s this guy who emails me his market outlook every so often.”\nThat’s howmy Barron’s column","content":"<div>\n<p>“So, there’s this guy who emails me his market outlook every so often.”\nThat’s howmy Barron’s column started one week nearly a dozen years ago, introducing the canny and clear-thinking financial ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/17/the-story-behind-the-savvy-mystery-broker-and-where-he-sees-the-market-going-now.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The story behind the savvy ‘Mystery Broker’ and where he sees the market going now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe story behind the savvy ‘Mystery Broker’ and where he sees the market going now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/17/the-story-behind-the-savvy-mystery-broker-and-where-he-sees-the-market-going-now.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>“So, there’s this guy who emails me his market outlook every so often.”\nThat’s howmy Barron’s column started one week nearly a dozen years ago, introducing the canny and clear-thinking financial ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/17/the-story-behind-the-savvy-mystery-broker-and-where-he-sees-the-market-going-now.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/07/17/the-story-behind-the-savvy-mystery-broker-and-where-he-sees-the-market-going-now.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1123523681","content_text":"“So, there’s this guy who emails me his market outlook every so often.”\nThat’s howmy Barron’s column started one week nearly a dozen years ago, introducing the canny and clear-thinking financial advisor who has come to be known in print and on Twitter as the Mystery Broker, whose market color and investment calls I share on the irregular frequency with which he sends them.\nHis predictions don’t always prove prescient, but he has been more right than wrong, with a particularly impressive record of bold calls around market bottoms and ahead of corrections.\nAs noted in that first writeup in Barron’s in December 2009: “This particular guy is unique in at least two respects. He has no interest in having his name placed in print or pixels. And he is the one commentator I’m aware of who both turned aggressively bearish virtually at the all-time market peak in 2007, then in April began insisting that the March market lows would not be challenged, and that a new cyclical bull market had a long way to run.”\nThis broker’s dispatch to me in April 2009 — just weeks after the ultimate low of a wrenching 18-month bear market and terrifying global credit crisis — was a 12-page single-spaced argument that the financial crisis was over.  This was far from the consensus at the time. A November 2007 piece had called for a brutal bear market, a month after the S&P 500 hit a peak it wouldn’t revisit until 2013 and before most investors even had a bear market on their radar.\nThe intention of airing his views was not to create some gimmick or generate cheap intrigue, but simply to offer the well-grounded thoughts of professional free of institutional constraints or the need to sell investment products.\nBut it did capture readers’ attention and imagination, to the point that requests for updates of the Mystery Broker’s market take come constantly. I continue it strictly because so many readers and viewers have followed his work for years and like to keep up\nAnd, yes, the whole exercise drives some people nuts, whether they think it’s irresponsible (which makes no sense, he gets no benefit and doesn’t hype small stocks that could move in his favor) or insist it’s a fictional alter ego (untrue).\nMystery Broker’s approach\nHe became a broker in the mid-’80s. While there’s long been a guessing game about MB’s identity, he is not someone who’s name anyone would know, he doesn’t otherwise comment publicly on investments.\nAs noted back in 2009: “He doesn’t claim any magic formulas or proprietary systems. His approach is eclectic and inclusive, ranging among economic, technical, historical, valuation and sentiment inputs.” He’ll cite Marty Zweig, Ned Davis and the Value Line Appreciation Potential indicators – fairly old-school inspirations – but doesn’t seem rigidly attached to any one model or style.\nI almost never solicit Mystery Broker’s take, preferring he check in only when it strikes him, often when he changes his market stance or is moved to reiterate his conviction in a prior call. Aside from the broad market commentary, he’ll sometimes make the case for or against individual stocks. He loved wells Fargo to start 2021, as well as GE, for instance.\nMystery Broker sometimes goes deep on a controversial emerging biotech name, the sort of thing I tend not to pass along. He was put off by CNBC’s heavy coverage of the “meme stocks” early this year and let me know it. He and I both have strong views on baseball, which we exchange via email. We’ve never met.\nHow he navigated the pandemic\nIn the past few months, Mystery Broker has been cautious on stocks and has missed a bit of upside. Specifically, he went to a sell (which tends to mean raising cash for clients and himself and hedging equity holdings with index puts) at the close on April 16, with the S&P 500 at 4185. The index went sideways for two months, then lifted to last week’s record up almost 5% from where he called for a correction.\nStill, he’s playing with a lot of house money, having been deftly bullish into the teeth of the March 2020 Covid crash. (He was negative on the market from January last year, though not because he expected either a pandemic or a crash).\nThe individual calls are viewable at the #MysteryBroker hashtag on Twitter, but to cite a few examples: He thought the March 4, 2020, low in the S&P 500 near 2900 would hold; it absolutely didn’t, plunging to about 2200 by the 23rd. But on March 26 he said the bottom was in, and within a month the S&P had recovered back to 2900.\nThen, this in mid-April 2020: He would normally look for a retest of the major low, but not then: ”“Because for the first time in stock market history the consensus is for a retest, a normal retest is not likely to happen.”\nThis was right, as was his preference for riskier cyclical stocks and his update June of last year: “We are in a new bull market...every correction should be bought...every time S&P 500 falls below its 50-day moving average is an extraordinary buying opportunity.”\nS&P 500 with 50-day moving averageFactSet\nAfter that and before predicting a correction three months ago that has yet to occur, he pegged the peak in FAANMG days before they topped last Sept. 1; said in late December the market had “entered the last hurrah for growth and speculative stocks” that would pressure the  overall market but not necessarily drive across-the-board losses; and predicted bitcoin would peak coincident with the Coinbase listing (it did). Not perfect, but not bad.\nHis current outlook\nHis is not a system, but a weight-of-the-evidence approach pursued with an open mind and a feel for market cadences earned over more than three decades of economic cycles.\nFollowing up onhis latest update this week, I asked for a broader take on historical echoes and longer-term probabilities. Mystery Broker offers this:\n“I think the current recovery is most similar to the recovery in 2003-04.  A big transition from hyper-growth to value.  Also, valuations are already high after only one year of stock market and economic growth similar to 2003-4, although more extreme now. ” He expects “muted returns for the rest of decade similar to the low returns of the first decade of the 2000s.  See leadership from industrials, healthcare and to some degree financials.”\n“Don’t expect technology to be a big outperformer and semiconductors will be a disappointment especially equipment semis that have benefitted from a few big trends over the last few years. Value, foreign stocks (expect dollar to fall over the next few years) and equal-weighted indices will outperform.  Inflation and interest rates will slowly rise which is different from the last decade.\n“The big surprise will be how old industries adapt to new technology and fight off some of the hot new entries.  There will be a lot of rebounds similar to how the New York Times came back from the dead last decade.”\nI also asked if he’s interested in being identified. The answer: not now, but maybe soon.","news_type":1},"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147629369,"gmtCreate":1626356701251,"gmtModify":1703758562623,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147629369","repostId":"2151526974","repostType":4,"repost":{"id":"2151526974","kind":"highlight","pubTimestamp":1626355620,"share":"https://ttm.financial/m/news/2151526974?lang=&edition=fundamental","pubTime":"2021-07-15 21:27","market":"us","language":"en","title":"3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2151526974","media":"Motley Fool","summary":"Analysts' high-water price targets imply some serious gains for these companies.","content":"<p>Despite the stock market hitting seemingly <a href=\"https://laohu8.com/S/AONE.U\">one</a> new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.</p>\n<p>But growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.</p>\n<h2>Vaxart: Implied upside of 158%</h2>\n<p>The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.</p>\n<p>For Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.</p>\n<p>But it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.</p>\n<p>Back on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.</p>\n<p>Though Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.</p>\n<h2>Columbia Care: Implied upside of 180%</h2>\n<p>Wall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is <b>Columbia Care</b> (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.</p>\n<p>Columbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.</p>\n<p>Although the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.</p>\n<p>Additionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.</p>\n<p>The last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.</p>\n<p>To be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 329%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.</p>\n<p>The bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.</p>\n<p>Inovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.</p>\n<p>On the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.</p>\n<p>What's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.</p>\n<p>In other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药","VXRT":"Vaxart, Inc"},"source_url":"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151526974","content_text":"Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.\nBut growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.\nVaxart: Implied upside of 158%\nThe first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.\nFor Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.\nBut it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.\nBack on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.\nThough Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.\nColumbia Care: Implied upside of 180%\nWall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is Columbia Care (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.\nColumbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.\nAlthough the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.\nAdditionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.\nThe last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.\nTo be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.\nInovio Pharmaceuticals: Implied upside of 329%\nBut the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.\nThe bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.\nInovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.\nOn the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.\nWhat's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.\nIn other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.","news_type":1},"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805611283,"gmtCreate":1627875248142,"gmtModify":1703496991419,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Hood","listText":"Hood","text":"Hood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805611283","repostId":"1123481231","repostType":4,"repost":{"id":"1123481231","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627873809,"share":"https://ttm.financial/m/news/1123481231?lang=&edition=fundamental","pubTime":"2021-08-02 11:10","market":"us","language":"en","title":"Ark Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=1123481231","media":"Benzinga","summary":"Tesla Inc(NASDAQ:TSLA) bull Cathie Wood-led Ark Invest sold some of the shares in the electric vehic","content":"<p><b>Tesla Inc</b>(NASDAQ:TSLA) bull&nbsp;<b>Cathie Wood</b>-led Ark Invest sold some of the shares in the electric vehicle maker months after setting a steep price target on the stock as the investment management firm re-balances its portfolio.</p>\n<p>The popular investment firm sold 63,643 shares, estimated to be worth about $43.7 million, in the&nbsp;<b>Elon Musk</b>-led company on a day Wood said Tesla will follow&nbsp;<b>Apple Inc</b>(NASDAQ:AAPL) in capturing the lion's share of the sector's profits.</p>\n<p>Wood compared Tesla with Apple in an interview with RealVision and suggested a huge inefficiency in analyst research behind Tesla, as reported by&nbsp;Markets Insider.</p>\n<p>“We believe that the reason there's such a big inefficiency in Tesla's valuation is the short-term time horizon of analysts and the wrong analysts following it,” Woods said, as per the report.</p>\n<p>The popular investment firm, which counts Tesla as its biggest holding, had in March said the stock will hit&nbsp;$3,000 at the end of 2025.</p>\n<p>The New York-based investment firm had on Monday deployed the&nbsp;<b>Ark Innovation ETF</b>(NYSE:ARKK) to sell the shares in Tesla and also holds the stock via two other traded funds, namely, the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(NYSE:ARKW).</p>\n<p>Ark Invest last sold shares in Tesla in April when shares of the company were trading around&nbsp;$719 a piece.</p>\n<p>All three Ark ETFs count Tesla among their largest positions and together held 4.9 million shares, worth $3.34 billion, ahead of Friday’s trades.</p>\n<p>The popular investment firm also scooped over 1.85 million shares, estimated to be worth about $65.2 million, in&nbsp;<b>Robinhood Markets Inc</b>(NASDAQ:HOOD) as the shares of the company staged a recovery and closed higher just a day after a dismal debut.</p>\n<p>Robinhood shares closed&nbsp;0.95% higher at $35.15 on Friday, a day after losing over 8% on its trading debut.</p>\n<p>Ark deployed ARKK, ARKW and the&nbsp;<b>Ark Fintech Innovation ETF</b>(NYSE:ARKF) to buy the shares in Robinhood and the three ETFs held 4.6 million shares, worth $160.5 million, in Robinhood Markets.</p>\n<p>Some of the other key Ark Invest buys on Friday included&nbsp;<b>Pinterest Inc</b>(NYSE:PINS), and&nbsp;<b>UiPath Inc</b>(NYSE:PATH), and sells included&nbsp;<b>Pinduoduo Inc</b>(NASDAQ:PDD).</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ark Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArk Sells $43.7M In Tesla While Cathie Wood Likens Elon Musk Company To Apple\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-02 11:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tesla Inc</b>(NASDAQ:TSLA) bull&nbsp;<b>Cathie Wood</b>-led Ark Invest sold some of the shares in the electric vehicle maker months after setting a steep price target on the stock as the investment management firm re-balances its portfolio.</p>\n<p>The popular investment firm sold 63,643 shares, estimated to be worth about $43.7 million, in the&nbsp;<b>Elon Musk</b>-led company on a day Wood said Tesla will follow&nbsp;<b>Apple Inc</b>(NASDAQ:AAPL) in capturing the lion's share of the sector's profits.</p>\n<p>Wood compared Tesla with Apple in an interview with RealVision and suggested a huge inefficiency in analyst research behind Tesla, as reported by&nbsp;Markets Insider.</p>\n<p>“We believe that the reason there's such a big inefficiency in Tesla's valuation is the short-term time horizon of analysts and the wrong analysts following it,” Woods said, as per the report.</p>\n<p>The popular investment firm, which counts Tesla as its biggest holding, had in March said the stock will hit&nbsp;$3,000 at the end of 2025.</p>\n<p>The New York-based investment firm had on Monday deployed the&nbsp;<b>Ark Innovation ETF</b>(NYSE:ARKK) to sell the shares in Tesla and also holds the stock via two other traded funds, namely, the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(NYSE:ARKW).</p>\n<p>Ark Invest last sold shares in Tesla in April when shares of the company were trading around&nbsp;$719 a piece.</p>\n<p>All three Ark ETFs count Tesla among their largest positions and together held 4.9 million shares, worth $3.34 billion, ahead of Friday’s trades.</p>\n<p>The popular investment firm also scooped over 1.85 million shares, estimated to be worth about $65.2 million, in&nbsp;<b>Robinhood Markets Inc</b>(NASDAQ:HOOD) as the shares of the company staged a recovery and closed higher just a day after a dismal debut.</p>\n<p>Robinhood shares closed&nbsp;0.95% higher at $35.15 on Friday, a day after losing over 8% on its trading debut.</p>\n<p>Ark deployed ARKK, ARKW and the&nbsp;<b>Ark Fintech Innovation ETF</b>(NYSE:ARKF) to buy the shares in Robinhood and the three ETFs held 4.6 million shares, worth $160.5 million, in Robinhood Markets.</p>\n<p>Some of the other key Ark Invest buys on Friday included&nbsp;<b>Pinterest Inc</b>(NYSE:PINS), and&nbsp;<b>UiPath Inc</b>(NYSE:PATH), and sells included&nbsp;<b>Pinduoduo Inc</b>(NASDAQ:PDD).</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","ARKQ":"ARK Autonomous Technology & Robotics ETF","ARKW":"ARK Next Generation Internation ETF","ARKF":"ARK Fintech Innovation ETF","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123481231","content_text":"Tesla Inc(NASDAQ:TSLA) bull Cathie Wood-led Ark Invest sold some of the shares in the electric vehicle maker months after setting a steep price target on the stock as the investment management firm re-balances its portfolio.\nThe popular investment firm sold 63,643 shares, estimated to be worth about $43.7 million, in the Elon Musk-led company on a day Wood said Tesla will follow Apple Inc(NASDAQ:AAPL) in capturing the lion's share of the sector's profits.\nWood compared Tesla with Apple in an interview with RealVision and suggested a huge inefficiency in analyst research behind Tesla, as reported by Markets Insider.\n“We believe that the reason there's such a big inefficiency in Tesla's valuation is the short-term time horizon of analysts and the wrong analysts following it,” Woods said, as per the report.\nThe popular investment firm, which counts Tesla as its biggest holding, had in March said the stock will hit $3,000 at the end of 2025.\nThe New York-based investment firm had on Monday deployed the Ark Innovation ETF(NYSE:ARKK) to sell the shares in Tesla and also holds the stock via two other traded funds, namely, the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(NYSE:ARKW).\nArk Invest last sold shares in Tesla in April when shares of the company were trading around $719 a piece.\nAll three Ark ETFs count Tesla among their largest positions and together held 4.9 million shares, worth $3.34 billion, ahead of Friday’s trades.\nThe popular investment firm also scooped over 1.85 million shares, estimated to be worth about $65.2 million, in Robinhood Markets Inc(NASDAQ:HOOD) as the shares of the company staged a recovery and closed higher just a day after a dismal debut.\nRobinhood shares closed 0.95% higher at $35.15 on Friday, a day after losing over 8% on its trading debut.\nArk deployed ARKK, ARKW and the Ark Fintech Innovation ETF(NYSE:ARKF) to buy the shares in Robinhood and the three ETFs held 4.6 million shares, worth $160.5 million, in Robinhood Markets.\nSome of the other key Ark Invest buys on Friday included Pinterest Inc(NYSE:PINS), and UiPath Inc(NYSE:PATH), and sells included Pinduoduo Inc(NASDAQ:PDD).","news_type":1},"isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173961398,"gmtCreate":1626601300814,"gmtModify":1703762232512,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173961398","repostId":"1139907709","repostType":4,"repost":{"id":"1139907709","kind":"news","pubTimestamp":1626568617,"share":"https://ttm.financial/m/news/1139907709?lang=&edition=fundamental","pubTime":"2021-07-18 08:36","market":"us","language":"en","title":"Wall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World","url":"https://stock-news.laohu8.com/highlight/detail?id=1139907709","media":"Benzinga","summary":"Does crime pay?\nIn August 1988, French authorities arrested an American expatriate named Thomas F. Q","content":"<p><i>Does crime pay?</i></p>\n<p>In August 1988, French authorities arrested an American expatriate named&nbsp;<b>Thomas F. Quinn</b>&nbsp;for orchestrating a global securities scheme that defrauded investors out of $500 million.</p>\n<p>As an unapologetic financial miscreant with a lifelong penchant for fraud, the French escapade represented something of a career peak for Quinn, whose flair of swindling took on an astonishing level of organizing that left no corner of the world untouched.</p>\n<p><b>Illusory Assets For Sale:</b>Thomas Francis Quinn was born in Brooklyn in 1932; his father drove a cement truck and his mother was a housewife who made extra money selling clothing and jewelry from the family’s garage.</p>\n<p>Quinn was an altar boy in his childhood and was the first member of his family to pursue higher education, graduating from St. John’s University Law School and passing the bar in 1962.</p>\n<p>Quinn opted to go into business for himself, starting a brokerage firm in New York called&nbsp;<b>Thomas, Williams &amp; Lee.</b>The main focus of this firm became the promotion of&nbsp;<b>Kent Industries,</b>a company that claimed to own Florida property valued at $2 million.</p>\n<p>There was a slight problem —&nbsp;Kent Industries didn’t own anything in the Sunshine State, and this inconvenient fact helped to introduce Quinn to the U.S. Securities and Exchange Commission (SEC).</p>\n<p>Long story short: Quinn received a lifetime banishment from the SEC in 1966 from doing business with brokers and dealers thanks to what the agency defined as his “flagrant fraudulent practices” related to the Kent Industries assets, which the regulator considered to be “almost completely illusory.”</p>\n<p>The U.S. Department of Justice (DOJ) was a bit slower in dealing with Quinn, but by 1970 he was sent to jail for six months and was later permanently disbarred from practicing law.</p>\n<p><b>A Job With The Mob:</b>Prior to losing his law license, Quinn gained a partnership in a New York-based securities law firm that set off several alarms among federal law enforcement agencies. Indeed, an FBI report from 1983 recalled this firm’s chief focus was being responsible for the “funds of hoodlum-controlled companies.”</p>\n<p>Quinn was on both the FBI’s and SEC’s respective radars in the early 1980s for his role with two companies,<b>Sundance Gold Mining</b>&nbsp;and&nbsp;<b>Aquarius Gold Exploration</b>, that claimed to have discovered gold in Suriname. The companies created a flurry of excitement among investors, but an investigation into their operations found a hitherto undeclared connection with the&nbsp;<b>Genovese crime family.</b></p>\n<p>The SEC filed a civil complaint against Quinn in 1983, charging him with fraudulently manipulating and promoting the companies’ stocks.</p>\n<p>Three years later, he reached a settlement with the regulator by agreeing to permanently stay away from anything related to securities.</p>\n<p>The FBI, despite finding Mafia fingerprints in Quinn’s business affairs, declined to press charges against him.</p>\n<p>Realizing that he wore out his welcome in his home country, Quinn and his common-law wife&nbsp;<b>Rochelle Rothfleisch</b>&nbsp;decided to relocate to France and to up his game to an unprecedented operation.</p>\n<p><b>Boiler Room Follies:</b>The circumstances and details of how Quinn built his swindling masterpiece are a bit fuzzy, but it is believed that the scheme was first hatched in 1984 and was coordinated out of his $6 million villa in the south of France.</p>\n<p>Quinn set up an archipelago of offices in several European countries and in Dubai, Jamaica and the tiny South Pacific island nation of Vanuatu, and he gave them phony names that sounded similar to respectable brokerages.</p>\n<p>Each office was staffed with salesmen who were tasked to sell stocks for 20 U.S. corporations to individual investors around the world. The stocks in question were mostly shell companies trading on the over-the-counter exchanges that Quinn picked up for pennies, but they were resold by Quinn’s salesmen at inflated amounts.</p>\n<p>The investors were culled from mailing lists sold by publishing companies and professional organizations, as well as from respondents to advertisements placed in newsletters focused on the over-the-counter markets.</p>\n<p>Quinn’s henchmen would telephone the investors —&nbsp;nearly all of whom were novices to investing —&nbsp;and do a high-pressure sales spiel that, more often than not, resulted in the separation of the gullible targets from their money.</p>\n<p>Quinn’s team aimed at European, Australian, Middle Eastern and Hong Kong neophyte investors. The only country off-limits from this scheme was the U.S. Quinn was already on the FBI’s radar and the last thing he wanted was to give them cause to pursue him anew.</p>\n<p><b>A Temporary Setback:</b>&nbsp;In 1988, Quinn’s arrest in France&nbsp;saw him charged with securities fraud, forgery of administrative documents and the possession of two fake Greek passports. His detention and the subsequent arrest of 20 of his salesmen created a fascinating dilemma for banking and law enforcement agencies in multiple countries.</p>\n<p>For starters, no one could easily figure out where the majority of Quinn’s $500 million in ill-gotten gains wound up.&nbsp;Transfers were traced through banks in Switzerland, Luxembourg and Gibraltar, as well as the beleaguered&nbsp;<b>Bank of Credit and Commerce International</b>&nbsp;in Tampa, Florida, which gained national attention as a favored depository for those involved in drug money laundering. But where the money eventually landed was anyone’s guess, and Quinn’s talent for adopting aliases to cover his business tracks confounded investigators.</p>\n<p>Also, it was unclear regarding how many people were swindled. A pair of class-action lawsuits brought out a total of 500 people trying to regain their money, but some observers of this case speculated the number could have been higher — some investors might have seen Quinn’s scam as a means of evading local taxes and foreign currency exchanges and would then have to answer to their authorities if this chicanery came to light.</p>\n<p>The SEC got into the picture because the stocks being sold in the scheme were all U.S. companies. The agency hosted a meeting in Washington D.C.&nbsp;with law enforcement officers and prosecutors from eight European countries and Australia, with the hopes of sorting out the mess. But since no Americans were defrauded in this elaborate charade, Quinn did not face criminal charges in his own country, although the SEC temporarily froze his U.S. assets.</p>\n<p>In France, Quinn was initially released after agreeing to reimburse his French victims but was arrested again when the Swiss government demanded his extradition.</p>\n<p>He came to trial in 1991 and was only sentenced to four years in prison,&nbsp;but his sentence was reduced to include time served and he was extradited to Switzerland.</p>\n<p>His Alpine detention was brief and by the mid-1990s he returned to the U.S. and rented a luxury home in Greenwich, Connecticut, a swanky suburb of New York City.</p>\n<p><b>An Eventual Stumble:</b>One of Quinn’s neighbors in Greenwich was<b>Martin Frankel,</b>a financier with his own addiction to swindling.</p>\n<p>In 1999, the Wall Street Journal used anonymous “people familiar with the matter” to claim Quinn assisted Frankel in his efforts to raise money for a controlled investment fund designed to buy insurance companies —&nbsp;but this turned out to be an embezzlement scam that resulted in Frankel fleeing the U.S. to Germany on a phony passport.</p>\n<p>Frankel was eventually extradited and spent nearly two decades in prison, but Quinn was never charged for being a partner in Frankel’s shenanigans.</p>\n<p>For most of the 1990s and the 2000s, Quinn kept a very low public profile, although law enforcement tracked his travels to such far-flung places as the Maldives and the United Arab Emirates.</p>\n<p>In 2004, he made a rare appearance at the Irish Derby as the co-owner of the winning thoroughbred Grey Swallow. Photographs of Quinn with the winning racehorse marked the only time that he was ever photographed in a public gathering. (Copyright restrictions prevent us from reprinting the photograph here, butthis linkon the RTE website shows Quinn, standing second from right, at the conclusion of the championship race.)</p>\n<p>In November 2009, Quinn’s luck finally ran out. On a trip back from Ireland to New York’s JFK International Airport, he was arrested for his role within a ring of embezzlers that sought to defraud a pair of British telecommunications companies out of more than $60 million. The scheme had the global hallmarks of Quinn’s earlier criminal triumph, with funds being disbursed to seven countries across four continents.</p>\n<p>Quinn was immediately jailed upon his arrest and was denied bail because it was feared he would attempt to flee the country. He eventually pleaded guilty to a single count of wire fraud and, despite exhortations to avoid prison due to health problems, he was sentenced in March 2013 to 84 months in prison. He was released in May 2016.</p>\n<p>What became of Quinn since his release is unknown. No obituary for him has been published, and he would be 89 years old if he is still alive.</p>\n<p>One information-tracking website listed him residing at a Brooklyn address, but the website also listed an accompanying telephone number that is not in service. Any readers who may have information on Quinn’s whereabouts should contact us and we will offer an update on his story.</p>\n<p>Quinn rarely spoke to anyone about his criminal activities.&nbsp;During an investigative session after his final arrest, he reportedly would only answer questions through a series of eyelid blinks. When a reporter sought to interview him in 1995, he demanded his privacy.</p>\n<p>\"Just forget me,\" Quinn said. \"I've got a lot of trouble and a lot of personal grief. I'm just trying to get on with my life. I'm not in the securities business and never will be again.\"</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Crime And Punishment: Thomas F. Quinn's Mad, Mad, Mad, Mad World\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/government/21/07/21990476/wall-street-crime-and-punishment-thomas-f-quinns-mad-mad-mad-mad-world><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Does crime pay?\nIn August 1988, French authorities arrested an American expatriate named Thomas F. Quinn for orchestrating a global securities scheme that defrauded investors out of $500 million.\nAs ...</p>\n\n<a href=\"https://www.benzinga.com/government/21/07/21990476/wall-street-crime-and-punishment-thomas-f-quinns-mad-mad-mad-mad-world\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/government/21/07/21990476/wall-street-crime-and-punishment-thomas-f-quinns-mad-mad-mad-mad-world","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139907709","content_text":"Does crime pay?\nIn August 1988, French authorities arrested an American expatriate named Thomas F. Quinn for orchestrating a global securities scheme that defrauded investors out of $500 million.\nAs an unapologetic financial miscreant with a lifelong penchant for fraud, the French escapade represented something of a career peak for Quinn, whose flair of swindling took on an astonishing level of organizing that left no corner of the world untouched.\nIllusory Assets For Sale:Thomas Francis Quinn was born in Brooklyn in 1932; his father drove a cement truck and his mother was a housewife who made extra money selling clothing and jewelry from the family’s garage.\nQuinn was an altar boy in his childhood and was the first member of his family to pursue higher education, graduating from St. John’s University Law School and passing the bar in 1962.\nQuinn opted to go into business for himself, starting a brokerage firm in New York called Thomas, Williams & Lee.The main focus of this firm became the promotion of Kent Industries,a company that claimed to own Florida property valued at $2 million.\nThere was a slight problem — Kent Industries didn’t own anything in the Sunshine State, and this inconvenient fact helped to introduce Quinn to the U.S. Securities and Exchange Commission (SEC).\nLong story short: Quinn received a lifetime banishment from the SEC in 1966 from doing business with brokers and dealers thanks to what the agency defined as his “flagrant fraudulent practices” related to the Kent Industries assets, which the regulator considered to be “almost completely illusory.”\nThe U.S. Department of Justice (DOJ) was a bit slower in dealing with Quinn, but by 1970 he was sent to jail for six months and was later permanently disbarred from practicing law.\nA Job With The Mob:Prior to losing his law license, Quinn gained a partnership in a New York-based securities law firm that set off several alarms among federal law enforcement agencies. Indeed, an FBI report from 1983 recalled this firm’s chief focus was being responsible for the “funds of hoodlum-controlled companies.”\nQuinn was on both the FBI’s and SEC’s respective radars in the early 1980s for his role with two companies,Sundance Gold Mining and Aquarius Gold Exploration, that claimed to have discovered gold in Suriname. The companies created a flurry of excitement among investors, but an investigation into their operations found a hitherto undeclared connection with the Genovese crime family.\nThe SEC filed a civil complaint against Quinn in 1983, charging him with fraudulently manipulating and promoting the companies’ stocks.\nThree years later, he reached a settlement with the regulator by agreeing to permanently stay away from anything related to securities.\nThe FBI, despite finding Mafia fingerprints in Quinn’s business affairs, declined to press charges against him.\nRealizing that he wore out his welcome in his home country, Quinn and his common-law wife Rochelle Rothfleisch decided to relocate to France and to up his game to an unprecedented operation.\nBoiler Room Follies:The circumstances and details of how Quinn built his swindling masterpiece are a bit fuzzy, but it is believed that the scheme was first hatched in 1984 and was coordinated out of his $6 million villa in the south of France.\nQuinn set up an archipelago of offices in several European countries and in Dubai, Jamaica and the tiny South Pacific island nation of Vanuatu, and he gave them phony names that sounded similar to respectable brokerages.\nEach office was staffed with salesmen who were tasked to sell stocks for 20 U.S. corporations to individual investors around the world. The stocks in question were mostly shell companies trading on the over-the-counter exchanges that Quinn picked up for pennies, but they were resold by Quinn’s salesmen at inflated amounts.\nThe investors were culled from mailing lists sold by publishing companies and professional organizations, as well as from respondents to advertisements placed in newsletters focused on the over-the-counter markets.\nQuinn’s henchmen would telephone the investors — nearly all of whom were novices to investing — and do a high-pressure sales spiel that, more often than not, resulted in the separation of the gullible targets from their money.\nQuinn’s team aimed at European, Australian, Middle Eastern and Hong Kong neophyte investors. The only country off-limits from this scheme was the U.S. Quinn was already on the FBI’s radar and the last thing he wanted was to give them cause to pursue him anew.\nA Temporary Setback: In 1988, Quinn’s arrest in France saw him charged with securities fraud, forgery of administrative documents and the possession of two fake Greek passports. His detention and the subsequent arrest of 20 of his salesmen created a fascinating dilemma for banking and law enforcement agencies in multiple countries.\nFor starters, no one could easily figure out where the majority of Quinn’s $500 million in ill-gotten gains wound up. Transfers were traced through banks in Switzerland, Luxembourg and Gibraltar, as well as the beleaguered Bank of Credit and Commerce International in Tampa, Florida, which gained national attention as a favored depository for those involved in drug money laundering. But where the money eventually landed was anyone’s guess, and Quinn’s talent for adopting aliases to cover his business tracks confounded investigators.\nAlso, it was unclear regarding how many people were swindled. A pair of class-action lawsuits brought out a total of 500 people trying to regain their money, but some observers of this case speculated the number could have been higher — some investors might have seen Quinn’s scam as a means of evading local taxes and foreign currency exchanges and would then have to answer to their authorities if this chicanery came to light.\nThe SEC got into the picture because the stocks being sold in the scheme were all U.S. companies. The agency hosted a meeting in Washington D.C. with law enforcement officers and prosecutors from eight European countries and Australia, with the hopes of sorting out the mess. But since no Americans were defrauded in this elaborate charade, Quinn did not face criminal charges in his own country, although the SEC temporarily froze his U.S. assets.\nIn France, Quinn was initially released after agreeing to reimburse his French victims but was arrested again when the Swiss government demanded his extradition.\nHe came to trial in 1991 and was only sentenced to four years in prison, but his sentence was reduced to include time served and he was extradited to Switzerland.\nHis Alpine detention was brief and by the mid-1990s he returned to the U.S. and rented a luxury home in Greenwich, Connecticut, a swanky suburb of New York City.\nAn Eventual Stumble:One of Quinn’s neighbors in Greenwich wasMartin Frankel,a financier with his own addiction to swindling.\nIn 1999, the Wall Street Journal used anonymous “people familiar with the matter” to claim Quinn assisted Frankel in his efforts to raise money for a controlled investment fund designed to buy insurance companies — but this turned out to be an embezzlement scam that resulted in Frankel fleeing the U.S. to Germany on a phony passport.\nFrankel was eventually extradited and spent nearly two decades in prison, but Quinn was never charged for being a partner in Frankel’s shenanigans.\nFor most of the 1990s and the 2000s, Quinn kept a very low public profile, although law enforcement tracked his travels to such far-flung places as the Maldives and the United Arab Emirates.\nIn 2004, he made a rare appearance at the Irish Derby as the co-owner of the winning thoroughbred Grey Swallow. Photographs of Quinn with the winning racehorse marked the only time that he was ever photographed in a public gathering. (Copyright restrictions prevent us from reprinting the photograph here, butthis linkon the RTE website shows Quinn, standing second from right, at the conclusion of the championship race.)\nIn November 2009, Quinn’s luck finally ran out. On a trip back from Ireland to New York’s JFK International Airport, he was arrested for his role within a ring of embezzlers that sought to defraud a pair of British telecommunications companies out of more than $60 million. The scheme had the global hallmarks of Quinn’s earlier criminal triumph, with funds being disbursed to seven countries across four continents.\nQuinn was immediately jailed upon his arrest and was denied bail because it was feared he would attempt to flee the country. He eventually pleaded guilty to a single count of wire fraud and, despite exhortations to avoid prison due to health problems, he was sentenced in March 2013 to 84 months in prison. He was released in May 2016.\nWhat became of Quinn since his release is unknown. No obituary for him has been published, and he would be 89 years old if he is still alive.\nOne information-tracking website listed him residing at a Brooklyn address, but the website also listed an accompanying telephone number that is not in service. Any readers who may have information on Quinn’s whereabouts should contact us and we will offer an update on his story.\nQuinn rarely spoke to anyone about his criminal activities. During an investigative session after his final arrest, he reportedly would only answer questions through a series of eyelid blinks. When a reporter sought to interview him in 1995, he demanded his privacy.\n\"Just forget me,\" Quinn said. \"I've got a lot of trouble and a lot of personal grief. I'm just trying to get on with my life. I'm not in the securities business and never will be again.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147641989,"gmtCreate":1626357526641,"gmtModify":1703758593400,"author":{"id":"3579087512345738","authorId":"3579087512345738","name":"Soapsoap","avatar":"https://static.tigerbbs.com/c0191be821dbc7d029d7b53385b0778c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579087512345738","authorIdStr":"3579087512345738"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147641989","repostId":"2151526974","repostType":4,"repost":{"id":"2151526974","kind":"highlight","pubTimestamp":1626355620,"share":"https://ttm.financial/m/news/2151526974?lang=&edition=fundamental","pubTime":"2021-07-15 21:27","market":"us","language":"en","title":"3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2151526974","media":"Motley Fool","summary":"Analysts' high-water price targets imply some serious gains for these companies.","content":"<p>Despite the stock market hitting seemingly <a href=\"https://laohu8.com/S/AONE.U\">one</a> new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.</p>\n<p>But growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.</p>\n<h2>Vaxart: Implied upside of 158%</h2>\n<p>The first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.</p>\n<p>For Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.</p>\n<p>But it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.</p>\n<p>Back on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.</p>\n<p>Though Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.</p>\n<h2>Columbia Care: Implied upside of 180%</h2>\n<p>Wall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is <b>Columbia Care</b> (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.</p>\n<p>Columbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.</p>\n<p>Although the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.</p>\n<p>Additionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.</p>\n<p>The last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.</p>\n<p>To be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 329%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.</p>\n<p>The bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.</p>\n<p>Inovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.</p>\n<p>On the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.</p>\n<p>What's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.</p>\n<p>In other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药","VXRT":"Vaxart, Inc"},"source_url":"https://www.fool.com/investing/2021/07/15/3-small-cap-stocks-158-to-329-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151526974","content_text":"Despite the stock market hitting seemingly one new high after another since the year began, Wall Street still sees value in equities. That's because historically low lending rates and a rebounding U.S. and global economy bode well for the growth stocks that have led the market higher.\nBut growth isn't the only category analysts believe will outperform. Small-cap stocks -- companies with market caps ranging from $300 million to as high as $2 billion -- were absolutely pummeled during the coronavirus crash and now appear set to thrive. Based on the highest Wall Street price target for each of the following small-cap stocks, implied upside ranging from 158% to as much as 329% may await.\nVaxart: Implied upside of 158%\nThe first tiny tot that Wall Street appears to be really excited about is clinical-stage biotech stock Vaxart (NASDAQ:VXRT). A little over a month ago, analyst Yasmeen Rahimi at Piper Sander placed an $18 price target and an overweight rating on Vaxart. Based on its $6.99 closing price on July 12, we're talking about roughly 158% in implied upside over the next year.\nFor Rahimi, the selling point on Vaxart is the company's Vector-Adjuvant-Antigen Standardized Technology, or VAAST platform. This proprietary oral vaccine platform is deemed relatively low risk by Rahimi given the amount of clinical data readily available. Specifically, VAAST is designed to activate systemic and mucosal immunity in the nose, lungs, intestines, and mouth to help fight against airborne viruses, such as influenza and norovirus.\nBut it's not norovirus that's put Vaxart on the map in 2021. That honor goes to VXA-CoV2-1, the company's clinical-stage coronavirus disease 2019 (COVID-19) candidate. Vaxart's experimental treatment is unique in that it's a pill, not an injection. A pill would likely result in higher vaccination rates, and it would certainly be easier from a distribution and administration standpoint.\nBack on May 3, Vaxart released data from its phase 1 study involving VXA-CoV2-1, which showed demonstrable CD8 T-cell responses. While it was able to generate relatively impressive immune responses, the company's pill didn't produce high levels of neutralizing antibodies in trial participants, which diverges from what we've seen following traditional COVID-19 injections.\nThough Vaxart may have a promising pathway to treat norovirus, it has a steep hill to climb if it's to become relevant in the COVID-19 treatment space. It's probably a bit early to pass judgment either way, but Rahimi's price target is potentially a bit too aggressive for a clinical-stage drug developer.\nColumbia Care: Implied upside of 180%\nWall Street is also exceptionally bullish on the U.S. cannabis industry, with most multistate operators expected to fly. But one marijuana stock with particularly high upside, according to the high-water price target on Wall Street of more than $15 a share, is Columbia Care (OTC:CCHWF). If Wall Street's most aggressive price target comes to fruition, Columbia Care's shareholders could be reveling in a 180% gain over the coming 12 months.\nColumbia Care finds itself perfectly set up to take advantage of a rapidly growing cannabis market in the U.S. In total, 36 states have waved the green flag on medical weed, with half of those states legalizing consumption and/or adult-use sales. With Columbia Care primarily focused on serving medical pot customers for years, it was a pretty seamless transition to also servicing a larger pool of recreational weed clients.\nAlthough the company is generating healthy growth from its existing dispensaries -- 60% same-store sales growth in the first quarter from retail locations open in Q1 2020 -- its core strategy has involved making strategic acquisitions. Last month, the company closed a $240 million deal to acquire Green Leaf Medical, which added operational and in-development dispensaries in four states, as well as close to 400,000 square feet of cultivation and production capacity.\nAdditionally, the purchase of The Green Solution in September 2020 stood out, as it allowed Columbia Care to gobble up Colorado's largest vertically integrated cannabis operator. Colorado sports the second-highest annual weed sales in the U.S., behind only California.\nThe last thing to take note of is Columbia Care's focus on limited-license markets. States like Pennsylvania and Ohio cap the number of retail licenses they'll issue, as well as how many licenses a single business can hold. Meanwhile, Virginia assigns licenses by jurisdiction. The point is this: Columbia Care will be able to establish a presence in key markets without being overrun by competition.\nTo be clear, I believe Columbia Care has a very bright future. However, expecting a 180% climb in 12 months might be a bit much.\nInovio Pharmaceuticals: Implied upside of 329%\nBut the crème de la crème of upside opportunity, at least on this list, belongs to clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to Oppenheimer analyst Hartaj Singh, Inovio has a price target of $35, implying that it'll more than quadruple in value over the next year.\nThe bulk of Singh's thesis rests with INO-4800, the company's experimental COVID-19 vaccine candidate. Since Inovio's vaccines are DNA-based, Singh believes they can be modified easily to tackle new variants of the disease as they arise. Further, Singh points out that INO-4800 has a more stable shelf life than some of the more popular COVID-19 vaccines. For context, Inovio reported on May 10 that its mid-stage study involving INO-4800 was well-tolerated, with T cell immune responses observed in all age groups.\nInovio also has a relatively large pipeline for a company with a sub-$2 billion market cap. It has nearly a dozen different DNA-based candidates in clinical trials at the moment to treat everything from infectious diseases to cancer. Generally speaking, the more swings a drug developer gets to take, the more likely they are to hit a home run.\nOn the other hand, Inovio Pharmaceuticals has struck out swinging for more than four decades. This is to say that Inovio has yet to bring an approved product to market since its inception more than 40 years ago.\nWhat's more, INO-4800 wasn't exactly getting the red carpet treatment in the lucrative U.S. market. The U.S. Food and Drug Administration placed a partial clinical hold on Inovio's phase 2/3 trial to gather more info on INO-4800 and its delivery device, known as Cellectra. Months later, the U.S. government pulled funding for a late-stage trial of INO-4800, coercing the company to look internationally to conduct its large-scale study.\nIn other words, with a long history of disappointment in its wake, Inovio is the type of stock investors should avoid until it actually shows us the goods.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}